GTPase KRas – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry


The GTPase KRas pipeline drugs market research report outlays comprehensive information on the GTPase KRas targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Undisclosed, Infectious Disease, and Immunology which include indications of Solid Tumor, Non-Small Cell Lung Cancer, Unspecified, Epstein–Barr Virus (HHV-4) Infections, and Unspecified Immunological Disorders. It also reviews key players involved in GTPase KRas targeted therapeutics development with respective active and dormant or discontinued projects.


* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – GTPase KRas
Therapy Area
· Dermatology; Immunology; Infectious Disease; Oncology; Ophthalmology; Undisclosed
Key Mechanisms of Action
· GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC Inhibitor
Key Routes of Administration
· Oral; Parenteral; Intravenous; Intramuscular; Intraocular; Intravenous Drip; Intratumor; Topical; and Subcutaneous
Key Companies
· Revolution Medicines Inc; Singh Biotechnology LLC; Molecular Axiom LLC; Oblique Therapeutics AB; Nano Intelligent Biomedical Engineering Corp; Jacobio Pharmaceuticals Group Co Ltd; Boehringer Ingelheim International GmbH; Shanghai Allist Pharmaceuticals Co Ltd; Quanta Therapeutics Inc; and VRise Therapeutics Inc
Key Molecule Type
· Small Molecule; Monoclonal Antibody; Antisense RNAi Oligonucleotide; Synthetic Peptide; Oligonucleotide; Fusion Protein; Enzyme; mRNA Vaccine; Subunit Vaccine; and Vaccine


  • The report provides a snapshot of the global therapeutic landscape for GTPase KRas
  • The report reviews GTPase KRas targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in GTPase KRas targeted therapeutics and enlists all their major and minor projects
  • The report assesses GTPase KRas targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to GTPase KRas targeted therapeutics

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for GTPase KRas Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding GTPase KRas development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Key Players

1200 Pharma LLC; 280Bio Inc; 3D Medicines Inc; 3P Biotechnologies Inc; A2A Pharmaceuticals Inc; Abbisko Therapeutics Co Ltd; ACM Biolabs Pte Ltd; ADEL Inc; Adlai Nortye Biopharma Co Ltd; Aelin Therapeutics; Agastiya Biotech LLC; AIGEN Sciences Inc; Altamira Therapeutics Ltd; Amgen Inc; Anhorn Medicines Co Ltd; Anima Biotech Inc; Antengene Corp Ltd; Applied Pharmaceutical Science Inc; Araxes Pharma LLC; Arvinas Inc; Ascendo Biotechnology Inc; Ascentage Pharma Group International; Astellas Pharma Inc; AstraZeneca Plc; Autotac Bio Inc; Autotelic Bio Inc; Balto Pharmaceuticals Inc; BeiGene Ltd; Beta Pharma Inc; Betta Pharmaceuticals Co Ltd; BioArdis LLC; Biocytogen Pharmaceuticals (Beijing) Co Ltd; Biond Biologics Ltd; BioTheryX Inc; Boehringer Ingelheim International GmbH; BridgeBio Pharma Inc; Bristol-Myers Squibb Co; Cancer Research UK; CCM Biosciences Inc; Cellivery Therapeutics Inc; Ceptur Therapeutics Inc; Chia Tai Tianqing Pharmaceutical Group Co Ltd; China Pharmaceutical University; Chugai Pharmaceutical Co Ltd; Codiak BioSciences Inc; Cotinga Pharmaceuticals Inc; Cue Biopharma Inc; Curve Therapeutics Ltd; D3 Bio Inc; Dana-Farber Cancer Institute Inc; Development Center for Biotechnology; Eli Lilly and Co; Elicio Therapeutics Inc; Enfuego Therapeutics Inc; Epichem Pty Ltd; Erasca Inc; Ex Seven Research LLC; Fog Pharmaceuticals Inc; Frontier Medicines Corp; Genentech USA Inc; GenFleet Therapeutics (Shanghai) Inc; Gradalis Inc; Gritstone Bio Inc; Guangzhou BeBetter Medicine Technology Co Ltd; H. Lee Moffitt Cancer Center & Research Institute Inc; Hap10 Inc; HUYA Bioscience International LLC; Idience Co Ltd; Immuneering Corp; Immuxell Biotech Ltd; Indi Molecular Inc; InnoCare Pharma Ltd; InnoCure Therapeutics Inc; InnoPharmaScreen Inc; Innovent Biologics Inc; InteRNA Technologies BV; InventisBio Co Ltd; Jacobio Pharmaceuticals Group Co Ltd; Jiangsu Hansoh Pharmaceutical Group Co Ltd; Jiangsu Hengrui Medicine Co Ltd; Jiangxi Jemincare Group Co Ltd; Johnson & Johnson; Kestrel Therapeutics Inc; LA Cell Inc; Lead Discovery Center GmbH; Libera Bio SL; Longuide Limited Lab; Merck & Co Inc; Mirati Therapeutics Inc; Moderna Inc; Molecular Axiom LLC; MolGenie GmbH; Nano Intelligent Biomedical Engineering Corp; National Cheng Kung University; Neoregen Biotech; Nostrum Biodiscovery SL; Novartis AG; Oblique Therapeutics AB; Oncocross Co Ltd; Oncogenuity Inc; Oshida Novel Pharmatech; Oxford Vacmedix UK Ltd; pacDNA LLC; PeptiDream Inc; Pharos iBio Co Ltd; Plasfer Srl; Plexxikon Inc; Primary Peptides Inc; Quanta Therapeutics Inc; Redx Pharma Plc; ReNeuron Group Plc; Revolution Medicines Inc; Runjia (Suzhou) Pharmaceutical Technology Co Ltd; Seed Therapeutics Inc; Shanghai Allist Pharmaceuticals Co Ltd; Shanghai Junshi Biosciences Co Ltd; Shanghai Lingtai Biomedical Technology Co Ltd; Shanghai Yingli Pharmaceutical Co Ltd; Shenzhen Forward Pharmaceutical Co Ltd; Shouyao Holding Co Ltd; Sibylla Biotech Srl; Sichuan Huiyu Pharmaceutical Co Ltd; Sidney Kimmel Comprehensive Cancer Center; Silenseed Ltd; Singh Biotechnology LLC; SiVEC Biotechnologies LLC; Stemirna Therapeutics Ltd; Suzhou Zelgen Biopharmaceutical Co Ltd; Takeda Pharmaceutical Co Ltd; TheRas Inc; Tosk Inc; Tyligand Biotechnology (Shanghai) Co Ltd; UNC Lineberger Comprehensive Cancer Center; University College London; ValiRx Plc; Venquis Therapeutics; VRise Therapeutics Inc; West Lake Biomedical Technology (Hangzhou) Co Ltd; Yale University; Zai Lab Ltd; Zhejiang University; Zymedi

Table of Contents

Table of Contents

List of Tables

List of Figures


Global Markets Direct Report Coverage


Therapeutics Development

Drugs under Development by Stage of Development

Drugs under Development by Therapy Area

Drugs under Development by Indication

Drugs under Development by Companies

Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones




Secondary Research

Primary Research

Expert Panel Validation

Contact Us



List of Tables

Number of Drugs under Development by Stage of Development, 2024

Number of Drugs under Development by Therapy Areas, 2024

Number of Drugs under Development by Indication, 2024

Number of Drugs under Development by Companies, 2024

Drugs under Development by Companies, 2024

Number of Drugs by Stage and Mechanism of Actions, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Drugs, 2024

Discontinued Drugs, 2024


List of Figures

Number of Drugs under Development by Stage of Development, 2024

Number of Drugs under Development by Therapy Areas, 2024

Number of Drugs under Development by Indications, 2024

Number of Drugs by Stage and Mechanism of Actions, 2024

Number of Drugs by Routes of Administration, 2024

Number of Drugs by Stage and Routes of Administration, 2024

Number of Drugs by Molecule Types, 2024

Number of Drugs by Stage and Molecule Types, 2024

Frequently asked questions

Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts
Tel +44 20 7947 2745

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
5-Hydroxytryptamine Receptor 2A - Drugs In Development, 2024
$3,500 | June 2024
Mu Type Opioid Receptor - Drugs In Development, 2024
$3,500 | June 2024
GTPase KRas - Drugs In Development, 2024
$3,500 | June 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at GTPase KRas – Drugs In Development, 2024 in real time.

  • Access a live GTPase KRas – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.